Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Community Health's (CYH) Subsidiary to Clear Fraud Charges

Community Health Systems' (CYH) arm to settle whistleblower lawsuits alleging a wide-ranging misconduct in emergency rooms.

    Here's Why Medpace (MEDP) is a Great Momentum Stock

    Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Teladoc Leads Telehealth Thanks to its Virtual Care Solution

      Teladoc's (TDOC) vast product portfolio, client base, tie-ups and acquisitions make it a leader in the telehealth industry.

        Has Medpace Holdings (MEDP) Outpaced Other Medical Stocks This Year?

        Is (MEDP) Outperforming Other Medical Stocks This Year?

          Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

          Style Box ETF report for FYC

            Sreyoshi Mukherjee headshot

            Medical Services Boom Drives Healthcare: 3 Top Picks

            Considering the rising popularity of PBM, CRO and EHR in the U.S. Medical Services industry, these three picks might be money-spinning choices for investors.

              Acadia Healthcare to Benefit from Growing Behavioral Issues

              Acadia Healthcare (ACHC) is well placed to serve patients with increasing incidence of behavioral and mental health illness.

                HCA Healthcare Up 11% Since Q2, Will the Rally Continue?

                HCA Healthcare's (HCA) shares rallied led by strong second-quarter results.

                  Teladoc (TDOC) Up 26% in 22 Days, Will Upside Continue?

                  Teladoc (TDOC) shares gain on strong operating performance in second quarter.

                    Nalak Das headshot

                    VIX Plunges to 7-Month Low: 5 Top-Ranked Momentum Picks

                    Since stock market performance and volatility index move in opposite directions, this is an extremely positive sign for the U.S. stocks.

                      Why Teladoc (TDOC) Stock Has More Than Doubled in a Year

                      Teladoc (TDOC) continues to gain from high demand for its telehealth services.

                        4 Health Care Stocks Set to Beat Earnings Estimates in 4Q

                        This attractive sector has several companies with upside potential.

                          Zacks.com featured expert Kevin Matras highlights: M.D.C., Ruth???s Hospitality, Medpace and Xylem

                          Zacks.com featured expert Kevin Matras highlights: M.D.C., Ruth???s Hospitality, Medpace and Xylem

                            Kevin Matras headshot

                            Winning Stock Picks from the Top 4 Industries with the Biggest Job Growth

                            Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include MDC, RUTH, MEDP and XYL.

                              Will Higher Membership, Revenues Aid Cigna (CI) Q4 Earnings?

                              Cigna's (CI) Q4 earnings should likely be aided by higher revenues from its healthcare, global supplement units, partly offset by Medicare membership loss.

                                DaVita (DVA) Partners with Epic to Launch EHR for Patients

                                DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.

                                  Tirthankar Chakraborty headshot

                                  New Strong Buy Stocks for December 29th

                                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                                    AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?

                                    The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter

                                      Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?

                                      Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.

                                        Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?

                                        Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.

                                          What's in Store for Cardinal Health (CAH) in Q1 Earnings?

                                          Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.

                                            Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?

                                            Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.

                                              Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?

                                              In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.

                                                Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?

                                                McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.

                                                  PAREXEL's Acquisition by Pamplona Approved by Shareholders

                                                  The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.